Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer.

ABSTRACT:

Objective

The TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option. The aim of this study was to assess the cost effectiveness of durvalumab plus chemotherapy compared to placebo plus chemotherapy from the perspective of US and Chinese payers.

Methods

Based on clinical data from the TOPAZ-1 trial, a Markov model was developed to simulate 10-year life expectancy and total healthcare costs for patients with BTC. The treatment group received durvalumab in combination with chemotherapy and the control group received placebo plus chemotherapy. The primary outcomes analyzed included quality-adjusted li

SUBMITTER: Ye ZM 

PROVIDER: S-EPMC9950513 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature